InvestSMART

Cyclopharm Limited (ASX:CYC)

ALERT: Price-sensitive ASX Announcement for CYC
Current share price for CYC : $0.600 -0.235 (-28.14%)+
Announcement
Release
25 Feb 2026 5:12PM
Price at Release
$0.835
Full Release
download
Summary
Cyclopharm Limited's Preliminary Final Report for the year ending December 31, 2025, outlines significant financial movements, including a total revenue from contracts with customers amounting to $32.3 million, an increase from the previous year. The company reported a substantial net loss of $17.2 million for the year, reflecting challenges in operating costs and depreciation expenses. Key financial activities include substantial depreciation, amortization, and research expenses, alongside notable investments in property and equipment. Despite these challenges, Cyclopharm maintained a strong equity position with total equity of $27.1 million, supported by significant capital investments and strategic financial management. The report includes comprehensive details on cash flow, liabilities, and equity changes, indicating strategic efforts to manage financial performance amidst a challenging economic environment.
Key Points
  • Total revenue from contracts with customers reached $32.3 million.
  • The company reported a net loss of $17.2 million.
  • Substantial depreciation and amortization costs were incurred.
  • Research and development expenses were significant.
  • Investments in property and equipment were notable.
  • Cyclopharm maintained a strong equity position with total equity of $27.1 million.
  • Strategic financial management was evident despite economic challenges.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.